Post-earnings recap
Reported
Tue, Mar 30, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Terns Pharmaceutical reported a significant loss in EPS, which was expected given the lack of revenue data. Despite the disappointing earnings, the stock rose by 5.72%, likely due to investor optimism about future strategies discussed in the call. The lack of guidance may leave some investors cautious about the company's short-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.65 | N/A | -301.10% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions impacting performance. They highlighted a focus on long-term growth despite recent setbacks.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future strategies were discussed, but specific timelines were not provided.